Abstract

Background. Prediction of which laryngeal dysplasia cases will progress to cancer is poorly achieved. The differential expression of biomarkers in dysplastic and cancerous lesions may help to improve this.

Methods. We carried out a systematic review of laryngeal dysplasia biomarkers. Risk ratios were calculated for each biomarker. Individual study data were pooled only for the biomarker p53.

Conclusions. Currently there is no good evidence for the use of biomarkers in predicting the future behavior of laryngeal dysplastic lesions. Only 3 studies showed statistically significant results. Better reporting of studies using the REMARK (REporting recommendations for tumor MARKer prognostic studies) consensus guidelines should help to improve this in the future